Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 11/20 | 0.47 |
| ▸ | TMPRSS15 | P98073 | 11/20 | 0.47 |
| ▸ | ELANE | P08246 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008683 | 0.84 | PRSS1 (0.45) | PRSS1TMPRSS15NPSR1 | |
| SCHEMBL20008704 | 0.82 | PRSS1 (0.42) | PRSS1TMPRSS15 | |
| SCHEMBL18720224 | 0.81 | PRSS1 (0.43) | PRSS1TMPRSS15ELANENPSR1AKR1C3 | |
| SCHEMBL20008627 | 0.81 | PRSS1 (0.47) | PRSS1TMPRSS15MEN1CYP3A4KMT2A | |
| SCHEMBL20008701 | 0.81 | PRSS1 (0.53) | PRSS1TMPRSS15 | |
| SCHEMBL20008692 | 0.79 | F10 (0.39) | PRSS1TMPRSS15 | |
| SCHEMBL7324570 | 0.78 | MAPT (0.61) | PRSS1MEN1CYP3A4KMT2ATDP1 | |
| SCHEMBL7333430 | 0.76 | PRSS1 (0.57) | PRSS1TMPRSS15KMT2A | |
| SCHEMBL7329213 | 0.76 | ESR1 (0.52) | PRSS1TMPRSS15KMT2A | |
| SCHEMBL7330416 | 0.75 | PRSS1 (0.61) | PRSS1TMPRSS15NPSR1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885TMPRSS15 87/4885ELANE 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.